Oral minoxidil for hair loss: what the evidence shows

Key points

• Minoxidil tablets are approved (US, UK) only for severe high blood pressure. The US label carries a boxed warning that includes pericardial effusion. Hair loss is an off-label use [1][2].
• Our PubMed search found six randomized trials of oral minoxidil tablets for hair loss, all small (the ones with reported size: 65 to 90 people) and 6 to 9 months long [3][8][9][10][11][15].
• One meta-analysis of four randomized trials (279 people) found no difference from topical minoxidil in hair density, and more hypertrichosis (unwanted hair growth) with the tablets [4].
• Large pooled reviews of low-dose use mostly report mild effects, but they are uncontrolled. Serious fluid-retention events exist as case reports, and the rate is unknown [5][6][12][13].
• The @Hoostethics list puts oral minoxidil in C. Our verdict: partly supported (see below) [14].

What oral minoxidil is

Minoxidil was developed as a blood-pressure drug. Its topical solution and foam, sold for hair loss, are a separate product line covered in our topical minoxidil article. This article is about the tablets, used at much lower strengths than for blood pressure, for conditions such as androgenetic alopecia (pattern hair loss).

Regulatory status

United States (FDA). We read the tablet label as published in openFDA (generic minoxidil tablets, AvKARE, label effective 21 January 2026). It is indicated for severe hypertension that causes symptoms or organ damage and has not responded to a diuretic plus two other antihypertensives. The label’s boxed warning calls minoxidil a “powerful antihypertensive agent” that “may produce serious adverse effects”, including pericardial effusion that may progress to tamponade [1]. The label does not list hair loss. Use for hair loss is therefore off-label. It is a prescription-only drug.

United Kingdom (MHRA/emc). The summary of product characteristics for Loniten tablets (Pfizer, emc page updated 26 February 2026) lists “severe hypertension” as the indication, reports pericardial effusion “in about 3% - 5% of treated patients not on dialysis”, says hypertrichosis “occurs in most patients”, and is prescription only. It does not mention alopecia [2].

EU, Germany (EMA, BfArM): not checked. We found no national or EU authorization for hair loss in the sources we opened, but we did not search those registers.

Who decides. Because the drug is prescription-only and the hair indication is unlicensed, the decision belongs to a prescriber, who weighs heart, kidney and blood-pressure history. This page does not advise on that decision.

What the trials found

All figures below come from abstracts or PubMed records. Where a record did not give a number, we say so.

Study	Population	Design	Result	Funding
Penha et al., JAMA Dermatology 2024 [3]	90 men, pattern hair loss	Double-blind RCT, 24 weeks; oral 5 mg daily vs topical 5% twice daily	68 completed. No significant difference in frontal hair density; vertex photo score favored oral (24%, 95% CI 0 to 48). Hypertrichosis in 22 of 45 (49%) in the oral arm	Grant from the Brazilian Dermatology Society fund (FUNADERM)
Asilian et al., J Cosmet Dermatol 2024 [9]	65 patients, pattern hair loss	RCT, 6 months; oral 1 mg vs topical 5%	Hair diameter improved in both arms, no difference; photo density improved only in the topical arm	Not stated
Vahabi-Amlashi et al., Dermatol Ther 2021 [8]	72 women, female pattern hair loss	Triple-blind RCT, 9 months; oral 0.25 mg vs topical 2%	Both arms improved; density 102 to 115 vs 107 to 113 hairs/cm2, difference not significant	Not stated
Janaani et al., Arch Dermatol Res 2025 [10]	75 randomized (60 finished)	RCT, 32 weeks; oral vs topical vs PRP plus topical	Terminal hair density rose a median 47.5% (oral) vs 48% (topical); PRP combination did better than either	Not stated
Nascimento e Silva et al., JAAD 2022 [11]	Women, female pattern hair loss	RCT, oral 0.25 mg vs 1 mg	Record had no abstract; size and results not verified	Not verified
Ramos et al., JAAD 2020 [11]	Women, female pattern hair loss	RCT letter, oral 1 mg vs topical 5%	Record had no abstract; size and results not verified	Not verified

Two points about Penha et al.: its record gives 33 and 35 completers per arm but uses a denominator of 45 for adverse events, which the record does not explain [3]. The trial authors concluded that the oral dose did not show superiority over topical.

The meta-analysis by Sobral et al. (International Journal of Dermatology, 2025) pooled four randomized trials (279 people, 24 to 39 weeks). It found a standardized mean difference of 0.02 for hair density (95% CI -0.25 to 0.29) and -0.25 for hair diameter (95% CI -0.75 to 0.26). Hypertrichosis was more frequent with tablets (risk ratio 2.01, 95% CI 1.18 to 3.41). Its record states no funding [4].

So the randomized evidence answers one question: in short trials, tablets and topical minoxidil gave similar hair counts. It does not show that tablets beat placebo in a large trial, and none of the trials ran beyond nine months.

Larger but uncontrolled evidence

• A single-arm meta-analysis (Liu et al., Frontiers in Pharmacology, 2025; 27 studies, 2,933 patients; searches to October 2024) reported “significant improvement” in 35% (95% CI 22% to 49%) and any improvement in 47%. Adverse events occurred in 27% [7]. Single-arm means no comparison group, so these rates cannot be read as treatment effects.
• A pooled analysis of 14 studies and 442 patients (Jimenez-Cauhe et al., Dermatologic Therapy, 2020) could not pool efficacy because the studies differed too much [5].

Most of this literature is retrospective chart review. We counted the randomized trials from one PubMed search on 2026-11-08 and may have missed some, for example in other languages or in trials still listed as registered.

Risks and unknowns

Hypertrichosis is the most consistent finding: 24% of 442 patients in the pooled analysis, 49% in the Penha trial, and the main reason for stopping in another meta-analysis (34.6% of discontinuations) [3][5][6].

Fluid retention and circulation. In the pooled analysis, pedal edema occurred in 2%, postural hypotension in 1.1%, and heart-rate changes in 1.3% [5]. A meta-analysis of low-dose studies found no significant change in systolic blood pressure (mean difference -0.13 mmHg) or diastolic (-1.25 mmHg), and a small rise in heart rate (2.67 beats per minute, 95% CI 0.34 to 5.01). Its authors note the studies had no control groups and varied in how they monitored blood pressure [6].

Serious events. A 2022 JAAD Case Reports paper describes a healthy 40-year-old woman who developed pericardial and pleural effusions and generalized edema about three weeks after starting low-dose tablets. The authors attributed it to the drug after excluding other causes, and it resolved after stopping with diuretic treatment [12]. Letters have since reported further cases. We did not open those letters.

For scale, a cross-sectional ultrasound study of 100 people (51 on low-dose tablets, 49 not) found small effusions in 5.8% and 6% respectively, none symptomatic [13]. Its authors say the size and design limit conclusions. We could not verify its funding.

Not studied well: long-term use beyond nine months in randomized trials, pregnancy, people with heart or kidney disease (the people in whom the boxed warning matters most), and what happens to hair on stopping. Whether the label’s boxed warning applies at low strength is unsettled; no regulator we read addresses it.

What the source post claims, and how it holds up

On 22 October 2026 @Hoostethics posted a looksmaxxing tier list titled “ranking looksmaxxing techniques”, with oral minoxidil in C and topical minoxidil in D [14]. The post states no criteria.

Verdict: partly supported. A middle-low rank fits an unlicensed drug with small, short trials and a boxed warning on the licensed product. It does not fit the ranking of topical minoxidil below it: the topical product is the one with regulatory approval for hair loss in the US, while the tablets matched it in the randomized comparisons above rather than outperforming it [3][4]. A tier list cannot capture how strongly someone’s hair responds or what their heart history is.

Frequently asked questions

Is oral minoxidil approved for hair loss? No. In the US and UK, tablets are licensed for severe high blood pressure only. We did not check the EU or Germany [1][2].

Does it work better than topical minoxidil? In four pooled randomized trials (279 people) hair density and diameter did not differ significantly. The main difference was more hypertrichosis with tablets [4].

What are the serious risks? At blood-pressure strengths the labels describe pericardial effusion, with the UK label giving 3% to 5% of treated patients. At low strengths, serious effusions appear as rare case reports, and the true rate is unknown [2][12].

Who decides whether it is used? A prescriber. It is a prescription-only drug, and hair loss is an unlicensed use [1][2].

Sources

1. openFDA drug label API, “Minoxidil tablets (AvKARE), boxed warning and indications” (label effective 2026-01-21; read 2026-11-08). https://api.fda.gov/drug/label.json?search=openfda.generic_name:"minoxidil"+AND+boxed_warning:pericardial&limit=2 (set id 02d7399f-94cc-f718-f214-587301edd138)
2. Electronic Medicines Compendium, “Loniten Tablets 2.5 mg, SmPC” (updated 26 Feb 2026). https://www.medicines.org.uk/emc/product/4294/smpc
3. Penha et al., “Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial,” JAMA Dermatology (2024), PMID 38598226, via PubMed E-utilities. https://pubmed.ncbi.nlm.nih.gov/38598226/
4. Sobral et al., “Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials,” Int J Dermatol (2025), PMID 39425514. https://pubmed.ncbi.nlm.nih.gov/39425514/
5. Jimenez-Cauhe et al., “Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis,” Dermatol Ther (2020), PMID 32757405. https://pubmed.ncbi.nlm.nih.gov/32757405/
6. Chen et al., “Low-dose oral minoxidil does not significantly affect blood pressure: a systematic review and meta-analysis,” J Am Acad Dermatol (2025), PMID 39521141. https://pubmed.ncbi.nlm.nih.gov/39521141/
7. Liu et al., “Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review,” Front Pharmacol (2025), PMID 40567364. https://pubmed.ncbi.nlm.nih.gov/40567364/
8. Vahabi-Amlashi et al., Dermatol Ther (2021), PMID 34529341. https://pubmed.ncbi.nlm.nih.gov/34529341/
9. Asilian et al., J Cosmet Dermatol (2024), PMID 38031516. https://pubmed.ncbi.nlm.nih.gov/38031516/
10. Janaani et al., Arch Dermatol Res (2025), PMID 39954138. https://pubmed.ncbi.nlm.nih.gov/39954138/
11. Nascimento e Silva et al., J Am Acad Dermatol (2022), PMID 35077777; Ramos et al., J Am Acad Dermatol (2020), PMID 31473295 (citation records only). https://pubmed.ncbi.nlm.nih.gov/35077777/ ; https://pubmed.ncbi.nlm.nih.gov/31473295/
12. Dlova, Jacobs, Singh, “Pericardial, pleural effusion and anasarca: A rare complication of low-dose oral minoxidil for hair loss,” JAAD Case Reports (11 Aug 2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC9478873/
13. “Evaluation of Pericardial Effusions in Alopecia Patients on Low-Dose Oral Minoxidil Therapy,” J Drugs Dermatol (2024). https://jddonline.com/articles/evaluation-of-pericardial-effusions-in-alopecia-patients-on-low-dose-oral-minoxidil-therapy-S1545961624P8029X/
14. @Hoostethics on X, “ranking looksmaxxing techniques” (22 Oct 2026); text read through the fxtwitter mirror, tier placement taken from the project’s transcription of the image. https://x.com/Hoostethics/status/2113302148750758106
15. PubMed E-utilities search “oral minoxidil AND (alopecia OR hair) AND (RCT OR systematic review OR meta-analysis)” (run 2026-11-08), 55 records screened by title and publication type.

This article is information, not medical advice.